Enterprise Financial Services Has Lowered Position in Bristol Myers Squibb Co (BMY) by $734,706; As Abbott Labs (ABT) Market Value Declined, Shareholder Integrys Wealth Advisors Lowered Holding

February 20, 2018 - By Maria Brooks

Enterprise Financial Services Corp decreased its stake in Bristol Myers Squibb Co (BMY) by 52.31% based on its latest 2017Q3 regulatory filing with the SEC. Enterprise Financial Services Corp sold 11,662 shares as the company’s stock declined 1.04% while stock markets rallied. The institutional investor held 10,632 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $678,000, down from 22,294 at the end of the previous reported quarter. Enterprise Financial Services Corp who had been investing in Bristol Myers Squibb Co for a number of months, seems to be less bullish one the $112.58B market cap company. The stock decreased 0.03% or $0.02 during the last trading session, reaching $68.96. About 10.55 million shares traded or 47.02% up from the average. Bristol-Myers Squibb Company (NYSE:BMY) has declined 23.19% since February 20, 2017 and is downtrending. It has underperformed by 39.89% the S&P500.

Integrys Wealth Advisors Llc decreased its stake in Abbott Labs (ABT) by 14.78% based on its latest 2017Q3 regulatory filing with the SEC. Integrys Wealth Advisors Llc sold 31,873 shares as the company’s stock declined 3.42% while stock markets rallied. The institutional investor held 183,835 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $9.81 million, down from 215,708 at the end of the previous reported quarter. Integrys Wealth Advisors Llc who had been investing in Abbott Labs for a number of months, seems to be less bullish one the $104.73 billion market cap company. The stock increased 1.13% or $0.67 during the last trading session, reaching $60.17. About 7.85M shares traded or 12.40% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since February 20, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 105 analyst reports since July 24, 2015 according to SRatingsIntel. The stock has “Hold” rating by BMO Capital Markets on Thursday, August 31. The stock of Abbott Laboratories (NYSE:ABT) has “Hold” rating given on Monday, July 10 by BMO Capital Markets. Citigroup maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, October 19. Citigroup has “Neutral” rating and $5 target. Barclays Capital maintained the stock with “Overweight” rating in Thursday, January 25 report. The rating was downgraded by William Blair to “Market Perform” on Friday, January 29. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) rating on Monday, October 2. RBC Capital Markets has “Buy” rating and $55.0 target. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Monday, January 4 report. The stock has “Buy” rating by Guggenheim on Tuesday, January 2. The rating was maintained by Stifel Nicolaus on Friday, September 22 with “Buy”. Barclays Capital maintained Abbott Laboratories (NYSE:ABT) on Thursday, April 20 with “Overweight” rating.

Since September 22, 2017, it had 0 insider buys, and 7 selling transactions for $31.71 million activity. Shares for $5.43M were sold by Salvadori Daniel Gesua Sive on Monday, October 23. Contreras Jaime sold 52,700 shares worth $2.74M. Shares for $1.73 million were sold by Blaser Brian J on Wednesday, January 31. Ford Robert B sold $2.69M worth of stock.

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.01, from 0.88 in 2017Q2. It fall, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Moreover, First Foundation Advisors has 0.03% invested in Abbott Laboratories (NYSE:ABT). Moreover, Monarch Management has 2.08% invested in Abbott Laboratories (NYSE:ABT). The Georgia-based Benedict Financial Incorporated has invested 1.62% in Abbott Laboratories (NYSE:ABT). Stephens Ar reported 0.37% in Abbott Laboratories (NYSE:ABT). Sawgrass Asset Limited Liability Corporation holds 0.8% or 305,144 shares in its portfolio. Tctc Lc invested 0.4% in Abbott Laboratories (NYSE:ABT). Pura Vida Invests Limited Liability Corporation stated it has 80,000 shares. Teachers Insurance And Annuity Association Of America, New York-based fund reported 224,400 shares. Cambridge Inv Advsrs Inc has 180,515 shares for 0.13% of their portfolio. Lourd Capital reported 7,127 shares stake. Hartford Management holds 0.4% or 402,286 shares. Hall Laurie J Trustee stated it has 2.28% of its portfolio in Abbott Laboratories (NYSE:ABT). Freestone Ltd Liability owns 44,849 shares. Panagora Asset Mngmt Inc reported 56,112 shares. Norway-based Dnb Asset As has invested 0.13% in Abbott Laboratories (NYSE:ABT).

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.08, from 0.95 in 2017Q2. It improved, as 62 investors sold BMY shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares or 0.68% more from 1.10 billion shares in 2017Q2 were reported. Moreover, Blue Chip Ptnrs has 0.04% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 2,171 shares. Donaldson Ltd Liability invested 0.09% in Bristol-Myers Squibb Company (NYSE:BMY). Wealthtrust Fairport Ltd Liability Corp holds 0.04% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 6,377 shares. Moreover, Intrust National Bank & Trust Na has 0.41% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 19,663 shares. California Employees Retirement Sys has invested 0.39% in Bristol-Myers Squibb Company (NYSE:BMY). D E Shaw Incorporated owns 0.23% invested in Bristol-Myers Squibb Company (NYSE:BMY) for 2.40 million shares. Strategy Asset Managers Ltd Liability Corp has invested 1.36% in Bristol-Myers Squibb Company (NYSE:BMY). Beese Fulmer Mngmt holds 0.88% or 60,365 shares. Ardevora Asset Mngmt Llp owns 462,400 shares or 0.88% of their US portfolio. Advisor Prns Limited Co invested in 36,961 shares. Union Comml Bank Corp accumulated 4,125 shares or 0.09% of the stock. Schroder Inv Management Group Inc has invested 0.06% in Bristol-Myers Squibb Company (NYSE:BMY). Franklin Street Advsrs Nc holds 1.16% of its portfolio in Bristol-Myers Squibb Company (NYSE:BMY) for 110,668 shares. Meristem Ltd Liability Partnership reported 13,723 shares. Boys Arnold And holds 11,052 shares or 0.11% of its portfolio.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 7 have Buy rating, 3 Sell and 9 Hold. Therefore 37% are positive. Bristol-Myers Squibb Company had 73 analyst reports since July 28, 2015 according to SRatingsIntel. The firm has “Hold” rating by Jefferies given on Tuesday, March 15. The rating was maintained by Jefferies on Thursday, July 14 with “Hold”. On Wednesday, April 26 the stock rating was initiated by Robert W. Baird with “Outperform”. The firm has “Equal-Weight” rating given on Friday, September 9 by Barclays Capital. The firm has “Buy” rating given on Friday, January 22 by Berenberg. Citigroup maintained Bristol-Myers Squibb Company (NYSE:BMY) rating on Wednesday, October 25. Citigroup has “Buy” rating and $72.0 target. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Hold” rating given on Thursday, August 11 by Berenberg. BMO Capital Markets maintained it with “Sell” rating and $4700 target in Monday, June 5 report. The rating was maintained by Barclays Capital on Friday, October 13 with “Equal-Weight”. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Hold” rating given on Thursday, November 16 by Jefferies.

Since September 6, 2017, it had 1 insider purchase, and 2 selling transactions for $646,385 activity. On Wednesday, September 6 Caldarella Joseph C sold $560,400 worth of Bristol-Myers Squibb Company (NYSE:BMY) or 9,340 shares. Samuels Theodore R. II also bought $249,187 worth of Bristol-Myers Squibb Company (NYSE:BMY) shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: